| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.01 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |